Aadi Bioscience, Inc. (AADI)
NASDAQ: AADI · Real-Time Price · USD
3.210
+0.110 (3.55%)
At close: Dec 27, 2024, 4:00 PM
3.250
+0.040 (1.25%)
After-hours: Dec 27, 2024, 7:56 PM EST
Company Description
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.
Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.
Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Aadi Bioscience, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 89 |
| CEO | David Lennon |
Contact Details
Address: 17383 Sunset Boulevard, Suite A250 Pacific Palisades, California 90272 United States | |
| Phone | 424 744 8055 |
| Website | aadibio.com |
Stock Details
| Ticker Symbol | AADI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001422142 |
| CUSIP Number | 00032Q104 |
| ISIN Number | US00032Q1040 |
| Employer ID | 61-1547850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Lennon | Chief Executive Officer |
| Scott Giacobello | Chief Financial Officer |
| Scott Giacobello | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | SCHEDULE 13D/A | Filing |
| Dec 23, 2024 | SCHEDULE 13D/A | Filing |
| Dec 20, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 20, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 3, 2024 | 144 | Filing |
| Oct 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 30, 2024 | 8-K | Current Report |
| Sep 19, 2024 | 8-K | Current Report |